Synergy in anti-malarial pre-erythrocytic and transmission-blocking antibodies is achieved by reducing parasite density

File Description SizeFormat 
eLife.35213.pdfAccepted version980.54 kBAdobe PDFView/Open
Title: Synergy in anti-malarial pre-erythrocytic and transmission-blocking antibodies is achieved by reducing parasite density
Authors: Sherrard-Smith, E
Sala, KA
Betancourt, M
Upton, LM
Angrisano, F
Morin, MJ
Ghani, AC
Churcher, TS
Blagborough, AM
Item Type: Journal Article
Abstract: Anti-malarial pre-erythrocytic vaccines (PEV) target transmission by inhibiting human infection but are currently partially protective. It has been posited, but never demonstrated, that co-administering transmission-blocking vaccines (TBV) would enhance malaria control. We hypothesized a mechanism that TBV could reduce parasite density in the mosquito salivary glands, thereby enhancing PEV efficacy. This was tested using a multigenerational population assay, passaging Plasmodium berghei to Anopheles stephensi mosquitoes. A combined efficacy of 90.8% (86.7–94.2%) was observed in the PEV +TBV antibody group, higher than the estimated efficacy of 83.3% (95% CrI 79.1–87.0%) if the two antibodies acted independently. Higher PEV efficacy at lower mosquito parasite loads was observed, comprising the first direct evidence that co-administering anti-sporozoite and anti-transmission interventions act synergistically, enhancing PEV efficacy across a range of TBV doses and transmission intensities. Combining partially effective vaccines of differing anti-parasitic classes is a pragmatic, powerful way to accelerate malaria elimination efforts.
Issue Date: 19-Jun-2018
Date of Acceptance: 18-May-2018
ISSN: 2050-084X
Publisher: eLife Sciences Publications Ltd
Journal / Book Title: eLife
Volume: 7
Copyright Statement: © 2018 Sherrard-Smith et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Sponsor/Funder: Medical Research Council (MRC)
Bill & Melinda Gates Foundation
Medical Research Council (MRC)
Bill & Melinda Gates Foundation
PATH-Program for Appropriate Technology in Health
Funder's Grant Number: MR/K010174/1B
Publication Status: Published
Article Number: e35213
Appears in Collections:Faculty of Natural Sciences
Epidemiology, Public Health and Primary Care

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons